These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9833608)

  • 21. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible fatal interaction between protease inhibitors and methamphetamine.
    Hales G; Roth N; Smith D
    Antivir Ther; 2000 Mar; 5(1):19. PubMed ID: 10846588
    [No Abstract]   [Full Text] [Related]  

  • 24. Mortality reduced by ritonavir.
    AIDS Patient Care STDS; 1996 Jun; 10(3):184. PubMed ID: 11361625
    [No Abstract]   [Full Text] [Related]  

  • 25. [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():18-21. PubMed ID: 11373769
    [No Abstract]   [Full Text] [Related]  

  • 26. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function.
    Witzke O; Plentz A; Schäfers RF; Reinhardt W; Heemann U; Philipp T
    AIDS; 1997 May; 11(6):836-8. PubMed ID: 9143629
    [No Abstract]   [Full Text] [Related]  

  • 27. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
    Schmidt HH; Behrens G; Genschel J; Stoll M; Dejam A; Haas R; Manns MP; Schmidt RE
    Antivir Ther; 1999; 4(3):163-70. PubMed ID: 12731756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efavirenz's complications.
    GMHC Treat Issues; 1998 May; 12(5):6. PubMed ID: 11365477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
    Wit FW; van Leeuwen R; Weverling GJ; Jurriaans S; Nauta K; Steingrover R; Schuijtemaker J; Eyssen X; Fortuin D; Weeda M; de Wolf F; Reiss P; Danner SA; Lange JM
    J Infect Dis; 1999 Apr; 179(4):790-8. PubMed ID: 10068573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. To AIDS and back with Norvir, D4T, 3TC and nutritional therapies. An interview with Michael Golk.
    Golk M
    Posit Health News; 1998; (No 16):5-7. PubMed ID: 11365018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
    van der Lugt J; Autar RS; Ubolyam S; Garcia EF; Sankote J; Avihingsanon A; Chuenyam T; Cooper DA; Lange J; Phanuphak P; Wit F; Ruxrungtham K; Burger D;
    J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
    Mathe G; Morette C; Hallard M; Pontiggia P; Blanquet D; Hage F
    Acta Pharmacol Sin; 2002 Jan; 23(1):1-15. PubMed ID: 11860730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
    Moyle GJ
    AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
    [No Abstract]   [Full Text] [Related]  

  • 35. Nevirapine-plus-protease studies under way.
    AIDS Alert; 1996 Oct; 11(10):119. PubMed ID: 11363856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AmFAR extols FDA on rapid approval of two protease inhibitors.
    AIDS Patient Care STDS; 1996 Jun; 10(3):193-4. PubMed ID: 11361645
    [No Abstract]   [Full Text] [Related]  

  • 40. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.